Cullinan Therapeutics — Third Quarter 2026 Earnings Summary

Cullinan Therapeutics reported a net loss of $49.4 million for the third quarter of 2026 and holds $313.8 million in cash and investments, providing a runway into 2029. The company initiated a potentially registrational Phase 2 study for CLN-049 in relapsed or refractory acute myeloid leukemia and began a global Phase 1/2 study for velinotamig in autoimmune cytopenias. Additionally, a New Drug Application for zipalertinib in combination with chemotherapy for first-line EGFR ex20ins non-small cell lung cancer was submitted under the FDA's Real-Time Oncology Review program. Clinical data updates for CLN-978 in autoimmune diseases and CLN-049 in leukemia are scheduled for presentation in December 2026.